TRex Bio, Inc. Common stock

TRXB

市值 US$3.85億

SOUTH SAN FRANCISCO, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, today announced the closing of its initial public offering of 8,333,334 shares of its common stock at the initial public offering price of $14.00 per share.